Dispelling Doubts: Review Affirms Safety, Efficacy of Biosimilar Insulins

July 08, 2025

A recent review confirms the safety and efficacy of biosimilar insulins, addressing concerns and promoting their adoption for diabetes treatment.

Consumers and Providers Face Biosimilar Knowledge Hurdles

July 07, 2025

Australian Patients With IBD Switched to Biosimilar Infliximab Maintain Long-Term Persistence

July 05, 2025

The Top 5 Biosimilar Articles for the Week of June 30

July 04, 2025

Biosimilar SB12 Matches Eculizumab in PNH Treatment Across Diverse Patient Groups

July 03, 2025

The Top 5 Most-Read Gastroenterology Stories of 2023

December 25th 2023

By Skylar Jeremias

Article

The top 5 most-read gastroenterology stories of 2023 examined clinical data for adalimumab biosimilars, some Canadian regulatory news, and inflation rate predictions from Vizient.

Cencora's Brian Biehn and Corey Ford Recommend Adaptations for Biosimilar Regulatory Frameworks

December 24th 2023

By Skylar Jeremias

Video

Brian Biehn and Corey Ford from Cencora suggest improvements to current regulatory frameworks to better promote biosimilars for US patients and ensure market sustainability.

The Top 5 Most-Read Ophthalmology Stories of 2023

December 23rd 2023

By Skylar Jeremias

Article

The top 5 most-read ophthalmology stories of 2023 concerned clinical results, approvals, and launches for ranibizumab and aflibercept biosimilars.

The Top 5 Biosimilar Articles for the Week of December 18

December 22nd 2023

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of December 18th, 2023.

Assays Reveal Equivalence Between Adalimumab-aqvh and Humira

December 21st 2023

By Cameron Santoro

Article

Comprehensive assay research concluded similar structures, functions, and stability between reference adalimumab (Humira) and adalimumab-aqvh.

Q&A: Dr Kimberly Maxfield Explains How BsUFA III Will Advance the US Biosimilar Industry

December 20th 2023

By Skylar Jeremias

Article

At AMCP Nexus, Kimberly Maxfield, PhD, pharmacologist at the FDA, delved into how the third reauthorization of the Biosimilar User Fee Act (BsUFA III) will shape the American biosimilar market and improve development efficiency over the next few years.

FDA Approves Avzivi, the Fifth Biosimilar to Avastin

December 19th 2023

By Skylar Jeremias

Article

The FDA approved Bio-Thera Solutions’ Avzivi (bevacizumab-tnjn), the fifth biosimilar referencing Avastin (bevacizumab) to be approved in the United States.

BioRationality: In FDA We Trust—A Commentary on FDA Efforts to Educate Biosimilar Stakeholders

December 18th 2023

By Sarfaraz K. Niazi, PhD

Article

Sarfaraz K. Niazi, PhD, offers his perspective on FDA biosimilar education efforts and the role these efforts and stakeholder perspectives play in uplifting—or undermining—biosimilar adoption.

The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur

December 17th 2023

By Skylar Jeremias

Podcast

On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).

Enoxaparin Biosimilar Shows Similar Efficacy to Originator in Preventing Postoperative Subclinical Thrombosis

December 16th 2023

By Deana Ferreri, PhD

Article

The biosimilar Enoxa (enoxaparin), marketed in Tunisia, demonstrated equivalence in preventing subclinical postoperative thrombotic events in patients with digestive cancers to Sanofi’s Lovenox, in a randomized controlled trial.